Rhythm Q3 Revenue Jumps 80% to $92.1M; Cash of $320.9M Funds 24 Months
RYTM sits 16% above its 52-week low of $74.5 on elevated volume (9.4× avg).
Summary
Rhythm's Q3 2026 10-Q shows revenue of $92.1 million (up 80% year over year) and a $41.4 million net loss, with $320.9 million of cash and investments that management says funds operations for at least 24 months.
Key Events · Earnings and Guidance · RYTM
-
Q3 Revenue Up 80% to $92.1M
Product revenue rose to $92.1 million from $51.3 million a year earlier, with U.S. sales of $67.5 million (73% of product revenue) and international $24.7 million.
-
Net Loss Narrows to $41.4M
Q3 2026 net loss was $41.4 million, or $0.61 per share, versus $52.9 million ($0.82) a year ago; nine-month net loss was $146.3 million.
-
Cash Runway at Least 24 Months
Cash, equivalents and short-term investments totaled $320.9 million at September 30, 2026; management says existing resources plus the initial term loan fund operations for at least 24 months.
-
New Debt and LG Chem Obligations
The $750 million term loan carries SOFR+4.60% (1.00% floor) or base rate+3.60%, 1.00% OID, matures November 2, 2031 and requires $50 million minimum qualified cash; the LGC Amendment adds $350 million of fixed payments through September 2029 and milestones up to $405 million.
Analysis · RYTM · Life Sciences
Revenue of $92.1 million in Q3 2026 was up 80% from $51.3 million a year earlier, driven by the U.S. acquired hypothalamic obesity launch, and the quarterly net loss narrowed to $41.4 million from $52.9 million. The 10-Q also puts hard numbers on the two deals announced this morning: $320.9 million of cash and investments at September 30 plus the $250 million initial term loan tranche, which management says funds operations for at least 24 months, against new obligations of $350 million in fixed LG Chem payments and up to $750 million of term debt. The trade-off is real — SG&A rose 27% and R&D 14% — but the runway statement removes near-term financing risk.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RYTM was trading at $86.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $74.50 to $122.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.